- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Imatinib Mesylate in Chronic Myeloid Leukemia ; volume:28 ; number:01 ; year:2007 ; pages:5-6
Indian journal of medical & paediatric oncology ; 28, Heft 01 (2007), 5-6
- Contributor
-
Mishra, Pravas
- DOI
-
10.1055/s-0041-1733196
- URN
-
urn:nbn:de:101:1-2022051210110346075762
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mishra, Pravas
Other Objects (12)
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia